The BMAL1 rs7950226 polymorphism could lower the risk for MetS comorbidities (G vs. A p = 0.047, OR 0.79, 95% CI 0.62–1.00; GG vs. GA + AA p = 0.037, OR 0.75, 95% CI 0.58–0.98). Here, BMAL1 is linked to metabolic syndrome.